U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Status:
US Previously Marketed
Source:
Bradosol Bromide by Ciba
(1958)
Source URL:
First approved in 1958
Source:
Bradosol Bromide by Ciba
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Targets:


Domiphen bromide it is used for the treatment of Acute Infectious Dental Diseases. Domiphen bromide is a quaternary antiseptic with actions and uses similar to those of cationic surfactants. Domiphen bromide has potent activity on blockade of human ether-a-go-go related gene (HERG) channels.
Status:
US Previously Marketed
First approved in 1958
Source:
Kantrex by Bristol
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Kanamycin A is aminoglycoside anti-bacterial agent. Active against many strains of Gram-negative bacteria and Gram-positive Staphylococcus aureus and epidermis. Some strains of Mycobacterium bacterium are sensitive. Most active in alkaline solution. It binds to bacterial ribosomes and reduces mRNA translation hence reduces protein biosynthesis. However, it also exhibits some toxic effects towards mammalian cells.
Status:
Possibly Marketed Outside US
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
(1960)
Source URL:
First approved in 1958
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Mecetronium etilsulfate (MES) is a detergent and belongs to the group of surface-active ingredients. MES along with propan-2-ol and propan-1-ol is an ingredient of rub-in hand disinfectants. The antimicrobial contribution of MES in hand rubs is questionable. MES locks on the outermost layer of the skin (stratum corneum) for sustained bacterial reduction as long as 3 to 5 hours.
Status:
Possibly Marketed Outside US
Source:
Canada:BUTAMBEN
Source URL:
First approved in 1958
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Butamben is a local anesthetic. It is the ester of 4-aminobenzoic acid and butanol. It is one of three components in the topical anesthetic Cetacaine. The onset of Cetacaine-produced anesthesia is rapid (approximately 30 seconds) and the duration of anesthesia is typically 30-60 minutes, when used as directed. This effect is due to the rapid onset, but short duration of action of Benzocaine coupled with the slow onset, but extended duration of Tetracaine HCI and bridged by the intermediate action of Butamben.
Status:
Possibly Marketed Outside US
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
(1960)
Source URL:
First approved in 1958
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Mecetronium etilsulfate (MES) is a detergent and belongs to the group of surface-active ingredients. MES along with propan-2-ol and propan-1-ol is an ingredient of rub-in hand disinfectants. The antimicrobial contribution of MES in hand rubs is questionable. MES locks on the outermost layer of the skin (stratum corneum) for sustained bacterial reduction as long as 3 to 5 hours.
Status:
Possibly Marketed Outside US
Source:
NCT04704518: Phase 4 Interventional Completed Photorefractive Keratectomy
(2022)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Trehalose, a naturally occurring disaccharide of glucose that appears to function in an anhydrobiotic capacity in many organisms. Bioblast Pharma study trehalose in Phase 2 for treating patients with Oculopharyngeal Muscular Dystrophy (OPMD) and spinocerebellar ataxia, type 3. In OPMD trehalose prevents the aggregation of the pathological protein (PABPN1) in muscle cells, the hallmark of the disease, by stabilizing the protein, reducing the formation of protein aggregations, and promoting their clearance from cells through autophagy, thus preventing muscle cell death. Trehalose induces autophagy via mTOR independent pathway. It activates TFEB, a master controller of lysosomal biogenesis and autophagy, by inhibiting AKT which is a negative regulator of TFEB that acts by direct phosphorylation (and inhibition) of TFEB. In addition, trehalose protects cells from hypoxic and anoxic injury and suppresses protein aggregation. In vivo studies with trehalose show cellular and behavioral beneficial effects in animal models of neurodegenerative diseases. Trehalose was in phase III clinical trial to study if it was possible to use the drug as add-on therapy in Bipolar Depression. Also in combination with hyaluronate, it can be used to treat dry eye syndrome. Trehalose protects the epithelial cells on the ocular surface, improving their resistance to the daily stresses of dry environments and tear film changes in a dry eye.
Status:
Possibly Marketed Outside US
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
(1960)
Source URL:
First approved in 1958
Source:
Cetacaine Anesthetic by Cetylite Industries, Inc.
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Mecetronium etilsulfate (MES) is a detergent and belongs to the group of surface-active ingredients. MES along with propan-2-ol and propan-1-ol is an ingredient of rub-in hand disinfectants. The antimicrobial contribution of MES in hand rubs is questionable. MES locks on the outermost layer of the skin (stratum corneum) for sustained bacterial reduction as long as 3 to 5 hours.
Dexamethasone is an anti-inflammatory agent that is FDA approved for the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling and others. Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. Adverse reactions are: Glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur; muscle weakness; osteoporosis and others. Aminoglutethimide may diminish adrenal suppression by corticosteroids. Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.